Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and acyl glucuronide metabolites in stable thoracic transplant recipients

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 282-291

  Ting, Lillian S L ^a   Partovi, Nilufar ^b   Levy, Robert D ^a,c,d,e   Riggs, K Wayne ^a   Ensom, Mary H H ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Faculty of Medicine   (Serbia)

^d ST PAUL S HOSPITAL   (Canada)

^e British Columbia Transplant Society   (Canada)

^f CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Acyl glucuronide of mycophenolic acid; Mycophenolic acid; Mycophenolic acid glucuronide; Pharmacokinetics; Thoracic transplant

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; CYCLOSPORIN; GLUCURONIDE; IMMUNOSUPPRESSIVE AGENT; PHENOL DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT; LUNG; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLITE; ORGAN TRANSPLANTATION; PARAMETER; PLASMA; PRIORITY JOURNAL; ACYLATION; AGED; BLOOD; DOSE RESPONSE; DRUG INTERACTION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; ULTRAVIOLET SPECTROPHOTOMETRY;

ACYLATION; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHENOLS; SPECTROPHOTOMETRY, ULTRAVIOLET; TACROLIMUS;

EID: 47249106823     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318166eba0     Document Type: Article

References (75)

1. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995;345:1321-1325.
2. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61:1029-1037.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995; 60:225-232.
4. Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998;31: 317-322.
5. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
7. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the international society for heart and lung transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant. 2005;24:945-955.
8. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the international society for heart and lung transplantation: twenty-second official adult lung and heart-lung transplant report - 2005. J Heart Lung Transplant. 2005;24:956-967.
9. Johnston A, Holt DW. Immunosuppressant drugs - the role of therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52:61S-73S.
10. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
11. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33:1080-1081.
12. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
13. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45:419-422.
14. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics ofmycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
15. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit. 2006;28:95-101.
16. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant. 2007;7:1822-1831.
17. Patel CG, Harmon M, Gohh RY, et al. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Ther Drug Monit. 2007;29:87-95.
18. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
19. Shipkova M, Armstrong VW, Weber L, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit. 2002;24:390-399.
20. Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
21. Cussonneau X, Bolon-Larger M, Prunet-Spano C, et al. Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:674-678.
22. Gajarski RJ, Crowley DC, Zamberlan MC, et al. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant. 2004;4: 1495-1500.
23. Hummel M, Yonan N, Ross H, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant. 2007;21:18-23.
24. Seebacher G, Weigel G, Griesmacher A, et al. One and a half years of experience with mycophenolate mofetil (CellCept) in cardiac transplantation: a prospective, randomized study. Transplant Proc. 1999;31: 3291-3293.
25. Armstrong VW, Tenderich G, Shipkova M, et al. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit. 2005;27:315-321.
26. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant. 2003;22:587-590.
27. Vidal E, Cantarell C, Capdevila L, et al. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol. 2000;87:182-184.
28. Ensom MH, Partovi N, Decarie D, et al. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit. 2002;24:310-314.
29. Ting LS, Partovi N, Levy RD, et al. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. Ann Pharmacother. 2006;40:1509-1516.
30. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
31. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000; 19:1071-1076.
32. Ensom MH, Partovi N, Decarie D, et al. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother. 2003;37:1761-1767.
33. Ting LS, Decarie D, Ensom MH. Effect of acidification on protein binding of mycophenolic acid. Ther Drug Monit. 2007;29:132-133.
34. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280.
35. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001;34:17-22.
36. de Winter BC, Mathot RA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: Does it improve patient outcome? Exp Opin Drug Metab Toxicol. 2007;3:251-261.
37. Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics. 2007;17:321-330.
38. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
39. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
40. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006; 82:1004-1012.
41. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
42. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
43. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
44. Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005;27: 442-450.
45. Tan KK, Trull AK, Hue KL, et al. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther. 1993;53:544-554.
46. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
47. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22:20-26.
48. CellCept (mycophenolate mofetil) Drug Monograph. Roche Laboratory Inc; Nutley, NJ: 2003.
49. Yeung S, Tsang WK, Tong KL, et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. Transplant Proc. 2004;36:2084-2086.
50. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
51. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
52. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
53. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
54. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23: 35-38.
55. Deters M, Kirchner G, Koal T, et al. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-Omycophenolic acid glucuronide. Ther Drug Monit. 2005;27:132-138.
56. Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006;29:275-280.
57. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
58. Westley IS, Brogan LR, Morris RG, et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos. 2006;34:261-266.
59. Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem. 2002;39: 173-183.
60. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999;21:35-43.
61. Seebacher G, Mallinger R, Laufer G, et al. Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. Adv Exp Med Biol. 1998;431:801-803.
62. Tedesco-Silva H, Bastien MC, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005; 37:852-855.
63. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75:665-672.
64. Armstrong V, Heller T, Brandhorst G, et al. Relationship between free mycophenolic acid and hematologic side effects: Interim results from the FDCC study. Am J Transplant. 2006;6:344.
65. Gonzalez-Roncero FM, Gentil MA, Brunet M, et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc. 2005;37:3749-3751.
66. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520.
67. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
68. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000; 19:1071-1076.
69. Ensom MH, Partovi N, Decarie D, et al. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother. 2003;37:1761-1767.
70. Ensom MH, Partovi N, Decarie D, et al. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit. 2002;24:310-314.
71. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin. 2006;22:2355-2364.
72. Le Meur Y, Buchler M, Lavaud S, et al. Therapeutic drug monitoring of MMF: a randomized multicenter study comparing concentration controlled versus fixed dose in kidney transplant recipients. Am J Transplant. 2006;6:343-344.
73. Bloom R, Naraghi R, Cibrik DM, et al. Opticept trial: interim results of 6-month efficacy and safety of monitored mycophenolate mofetil (MMF) in combination with CNI in renal transplantation. Am J Transplant. 2006; 6:344.
74. Heller T, Armstrong VW, Brandhorst G, et al. Plasma concentrations of mycophenolic acid acyl glucuronide related to diarrhoea. Interim results from the FDCC study. Am J Transplant. 2006;6:344-345.
75. van Gelder T, Silva HT, de Fijter H, et al. A prospective, randomised study comparing fixed dose vs concentration controlled MMF regimens for de novo patients following renal transplantation (the FDCC trial). Am J Transplant. 2006;6:343.